基于欧盟从COVID-19大流行中吸取的经验,对未来的欧洲药品监管和市场准入实践:多方利益相关者采访的见解
Zilke Claessens1, Grace Beirne2, Catherine Decouttere2
1Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. zilke.claessens@kuleuven.be.
利益相关者发现加快COVID-19药物批准是有益的,但也指出了资源挑战. 建议侧重于改善未来卫生紧急情况和常规框架的合作和透明度.
科学领域:
- 制药政策和监管
- 卫生经济学和结果研究
- 公共卫生准备
背景情况:
- 由于COVID-19大流行,新药需要迅速采取监管和市场准入措施.
- 现有框架被调整为在卫生危机期间加快药物供应.
研究的目的:
- 在COVID-19期间收集多方利益相关者的观点, 加快监管和市场准入程序.
- 为优化日常和紧急医疗保健框架制定建议.
主要方法:
- 与欧洲政策制定者/顾问 (监管机构,HTA评估者,支付人) 和制药业代表进行半结构面试.
- 对转录的采访数据进行主题框架分析 (n=16).
主要成果:
- 快速程序 (如紧急工作组,滚动审查) 的确定的好处,包括缩短时间表,加强合作和灵活性.
- 突出了诸如资源分配效率低下和透明度下降等挑战.
- 建议改善互动,实用程序和明确的资格标准.
结论:
- 对于日常和紧急情况,COVID-19 经验为监管和市场准入实践提供了宝贵的见解.
- 利益相关方的反思对于提高未来卫生危机的准备和反应能力至关重要.
更多相关视频
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
相关概念视频
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Preclinical Development: Overview
Drug Regulation
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
